Akari Therapeutics Announces Existing Investors Support The Company Through A $2M Private Placement Financing, Company Also Receives $2.5M U.K. R&D Tax Credit
Portfolio Pulse from Benzinga Newsdesk
Akari Therapeutics (NASDAQ:AKTX) has announced a private placement of its equity securities with existing investors, including Chairman Dr. Ray Prudo and CEO Rachelle Jacques, expected to generate $2 million. The company also received a $2.5 million R&D tax credit from the UK. The private placement will involve the issuance of unregistered American Depository Shares (ADSs) at $3.30 per ADS. The closing is expected on September 22, 2023.
September 21, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akari Therapeutics is set to raise $2 million through a private placement and has received a $2.5 million R&D tax credit from the UK. This could provide a financial boost to the company.
The private placement and the R&D tax credit will provide Akari Therapeutics with additional funds, which could be used for further research and development, potentially leading to new products and increased revenues. This could have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100